Leiomyosarcoma epidemiology and demographics: Difference between revisions
Nima Nasiri (talk | contribs) |
Nima Nasiri (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
[[Leiomyosarcoma]] is a rare tumor subtype, accounts for 1% of all uterine malignancies, but contributes to a significant proportion of uterine cancer deaths. The incidence of uterine LMS is 0.36 per 100,000 woman-years [5]; most occur in women over 40 years of age, with incidence increasing rapidly after age 50 [9]. Black women have a 2-fold higher incidence than white women. LMS may be associated with obesity and diabetes [6]. Tamoxifen use for N5 years may also increase LMS risk to 17 per 100,000 woman-years [7]. Additionally, studies in soft tissue sarcoma have attributed an increased risk of LMS with p53 gene mutations, radiation treatment for childhood cancers, and germ line mutations in fumarate hydratase (hereditary leiomyomatosis with renal cell carcinoma) [4]. Most uterine LMS is unassociated with preexisting leiomyomas and no biologic evidence exists to link LMS with their benign, smooth muscle uterine tumors. <ref name="ToroTravis2006">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref> | [[Leiomyosarcoma]] is a rare tumor subtype, accounts for 1% of all uterine malignancies, but contributes to a significant proportion of uterine cancer deaths. The incidence of uterine LMS is 0.36 per 100,000 woman-years [5]; most occur in women over 40 years of age, with incidence increasing rapidly after age 50 [9]. Black women have a 2-fold higher incidence than white women. LMS may be associated with obesity and diabetes [6]. Tamoxifen use for N5 years may also increase LMS risk to 17 per 100,000 woman-years [7]. Additionally, studies in soft tissue sarcoma have attributed an increased risk of LMS with p53 gene mutations, radiation treatment for childhood cancers, and germ line mutations in fumarate hydratase (hereditary leiomyomatosis with renal cell carcinoma) [4]. Most uterine LMS is unassociated with preexisting leiomyomas and no biologic evidence exists to link LMS with their benign, smooth muscle uterine tumors. <ref name="ToroTravis2006">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref> | ||
Uterine sarcoma are extremely rare, with the incidence of 0.36 patients per 100,000 woman-years.<ref name="ToroTravis2006">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref> | Uterine sarcoma are extremely rare, with the incidence of 0.36 patients per 100,000 woman-years.<ref name="ToroTravis2006">{{cite journal|last1=Toro|first1=Jorge R.|last2=Travis|first2=Lois B.|last3=Wu|first3=Hongyu Julian|last4=Zhu|first4=Kangmin|last5=Fletcher|first5=Christopher D.M.|last6=Devesa|first6=Susan S.|title=Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases|journal=International Journal of Cancer|volume=119|issue=12|year=2006|pages=2922–2930|issn=00207136|doi=10.1002/ijc.22239}}</ref> | ||
Black women have a 2-fold higher incidence of development of the uterine Leiomyosarcoma as compared to the white women. | |||
Black women have a higher incidence of development of the uterine Leiomyosarcoma as compared to the white women. | |||
==References== | ==References== | ||
Revision as of 14:26, 28 February 2019
Overview:
Leiomyosarcoma is one the most common types of soft tissue sarcoma.
|
Leiomyosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Leiomyosarcoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Leiomyosarcoma epidemiology and demographics |
|
Risk calculators and risk factors for Leiomyosarcoma epidemiology and demographics |
Epidemiology and demographics
Leiomyosarcoma is a rare tumor subtype, accounts for 1% of all uterine malignancies, but contributes to a significant proportion of uterine cancer deaths. The incidence of uterine LMS is 0.36 per 100,000 woman-years [5]; most occur in women over 40 years of age, with incidence increasing rapidly after age 50 [9]. Black women have a 2-fold higher incidence than white women. LMS may be associated with obesity and diabetes [6]. Tamoxifen use for N5 years may also increase LMS risk to 17 per 100,000 woman-years [7]. Additionally, studies in soft tissue sarcoma have attributed an increased risk of LMS with p53 gene mutations, radiation treatment for childhood cancers, and germ line mutations in fumarate hydratase (hereditary leiomyomatosis with renal cell carcinoma) [4]. Most uterine LMS is unassociated with preexisting leiomyomas and no biologic evidence exists to link LMS with their benign, smooth muscle uterine tumors. [1]
Uterine sarcoma are extremely rare, with the incidence of 0.36 patients per 100,000 woman-years.[1] Black women have a 2-fold higher incidence of development of the uterine Leiomyosarcoma as compared to the white women.
References
- ↑ 1.0 1.1 Toro, Jorge R.; Travis, Lois B.; Wu, Hongyu Julian; Zhu, Kangmin; Fletcher, Christopher D.M.; Devesa, Susan S. (2006). "Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases". International Journal of Cancer. 119 (12): 2922–2930. doi:10.1002/ijc.22239. ISSN 0020-7136.